Actively Recruiting
Evaluating the Efficacy and Safety of Cellgram-LC Compared to Best Supportive Care in Adult Patients With Alcoholic Liver Cirrhosis
Led by Pharmicell Co., Ltd. · Updated on 2026-09-21
200
Participants Needed
15
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of Cellgram-LC, a biological treatment involving a single injection of autologous bone marrow-derived mesenchymal stem cells, in patients with alcoholic cirrhosis. This randomized, open-label Phase III trial compares Cellgram-LC with best supportive care BSC to determine if Cellgram-LC improves transplant-free survival and to identify any medical problems following treatment. Participants are assigned to one of two groups one group receives a single dose of Cellgram-LC through the hepatic artery at Week 0, and the other receives best supportive care. The study uses a parallel design with random allocation to these groups. Assessments occur at scheduled clinic visits at Week 4 and Months 3, 6, 9, 12, 18, and 24, along with telephone follow-ups at various months up to Month 36. During the study, participants undergo regular evaluations including liver function tests, fibrosis assessments, and quality of life questionnaires. Researchers measure transplant-free survival over three years as the primary outcome, along with survival rates, scores assessing liver function and fibrosis, and health status changes. The trial includes ongoing monitoring through clinic visits and telephone contacts, with total participation lasting up to 36 months.
CONDITIONS
Brief Title
Clinical Trial to Evaluate the Efficacy and Safety of Cellgram-LC Administration in Patients With Alcoholic Cirrhosis
Research Team
Y
YUJEONG KIM
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here